欢迎来到江苏苏博生物医学股份有限公司
首页>新闻资讯>行业资讯

2019年肿瘤基因检测进展盘点!

时间:2019-12-23  来源:互联网 


1.Wen SDai LWang Let al.Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.Oncologist. 2019 Nov;24(11):e1070-e1081.

2.Wu YLSaijo NThongprasert Set al.Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.Lung Cancer. 2017 Feb;104:119-125. 

3.Abstract LBA2_PR‘Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA will be presented by Dr Suresh Ramalingam during Presidential Symposium I on Saturday 9 September 2017, 16:30 to 18:00 (CEST) in the Madrid Auditorium.

4.Mehlman CCadranel J,et al.Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.Send to

Lung Cancer. 2019 Nov;137:149-156.

5.Liu P, Wang Y, Li X. Targeting the untargetable KRAS in cancer therapy. Acta Pharmaceutica Sinica B. 2019;9(5):871-879. doi: 10.1016/j.apsb.2019.03.002.

6.Gatalica ZXiu JSwensen JVranic S.Molecular characterization of cancers with NTRK gene fusions.Mod Pathol. 2019 Jan;32(1):147-153. 

7.Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. New England Journal of Medicine. 2018 Feb 22;378(8):731-9.

8.L. Paz-Ares, et al. Entrectinib in NTRK Fusion-Positive Non-Small Cell Lung Cancer (NSCLC): Integrated Analysis of Patients (pts) Enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001. Abstract 113O, Presented at ELCC Annual Meeting; April 10-13, 2019; Geneva.

9.Hyman D, Kummar S, Farago A, et al. Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi). Presented at: 2019 AACR Annual Meeting; March 29 to April 3, 2019; Atlanta, GA. Abstract CT127.

10.Helsten TElkin SArthur ETomson BNCarter JKurzrock R.The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.Clin Cancer Res. 2016 Jan 1;22(1):259-67. 

11.Loriot Yohann,Necchi Andrea,Park Se Hoon et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.[J] .N. Engl. J. Med., 2019, 381: 338-348.

12.Ledermann JADrew YKristeleit RSHomologous recombination deficiency and ovarian cancer.Eur J Cancer. 2016 Jun;60:49-58.

13.Nientiedt CTolstov YVolckmar AL,et al.PARP inhibition in BRCA2-mutated prostate cancer.Ann Oncol. 2017 Jan 1;28(1):189-191. 

14.Golan THammel PReni M,et al.Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.N Engl J Med. 2019 Jul 25;381(4):317-327.

15.Yi TFeng YSundaram R,et al.Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.Int J Cancer. 2019 Sep 1;145(5):1209-1220.

16.Helsten TElkin SArthur ETomson BNCarter JKurzrock R.The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.Clin Cancer Res. 2016 Jan 1;22(1):259-67. 

17.Audeh WBlumencranz LKling H,et al.Prospective Validation of a Genomic Assay in Breast Cancer: The 70-gene MammaPrint Assay and the MINDACT Trial.Acta Med Acad. 2019 Apr;48(1):18-34. 

18.Jia Xin Yu,Jeffrey P. Hodge,Cristina Oliva,et al.Trends in clinical development for PD-1/PD-L1 inhibitors, retrieved 2019/11/4.

19.Havel JJChowell DChan TA.The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.Nat Rev Cancer. 2019 Mar;19(3):133-150.

20.IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).J Clin Oncol 37, 2019 (suppl; abstr 1003).

21.Spigel D, de Marinis F, Giaccone G, et al. IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC. Program and abstracts of the European Society for Medical Oncology 2019 Congress; September 27-October 1, 2019; Barcelona, Spain. Abstract LBA78. 

22.Reck M,Rodríguez-Abreu D,Robinson AG,et al.KEYNOTE-024 3-Year Survival Update:Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer[EB/OL].WCLC 2019,abstract OA14.01;

23.Mok TSK,Wu YL,Kudaba I,et al.Pembrolizumab versus chemotherapy for previously untreated,PD-L1-expressing,locally advanced or metastatic non-small-cell lung cancer(KEYNOTE-042):a randomised,open-label,controlled,phase 3 trial[J].Lancet,2019,393(10183):1819-1830.

24.Hellmann MDPaz-Ares LBernabe Caro R,et al.Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.N Engl J Med. 2019 Nov 21;381(21):2020-2031. 

25.ASCO 2019 annual meeting. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase 3 KEYNOTE-181 study.Shah MAKojima THochhauser D,et al.Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180Study.JAMA Oncol. 2019 Apr 1;5(4):546-550. 

26.Matulonis U A, Frommer R S, Santin A D, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study[J]. Ann Oncol, 2019, 30:1080-1087.

27.Cao DXu HXu XGuo TGe W.High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients.Oncoimmunology. 2019 Jun 16;8(9):e1629258.

28.Paz-Ares L,Langer CJ,Novello S,et al.Pembrolizumab(pembro) plus platinum-based chemotherapy(chemo) for metastatic NSCLC:Tissue TMB(tTMB) and outcomes in KEYNOTE-021,189,and 407[EB/OL].ESMO 2019,abstract. 

29.Herbst RS,Lopes G,Kowalski DM,et al.Association between tissue TMB(tTMB) and clinical outcomes with pembrolizumab monotherapy(pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials[EB/OL].ESMO 2019,abstract  LBA79.

30.Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results. 2018 ASCO, Abs 12001.

31.Wang Z, Duan J, Cai S, et al. Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel. JAMA oncology, 2019.

32.Samstein Robert M,Lee Chung-Han,Shoushtari Alexander N et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types.[J] .Nat. Genet., 2019, 51: 202-206.

33.Chalmers ZRConnelly CFFabrizio DGay L, et al.Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.Genome Med. 2017 Apr 19;9(1):34.

34.Hause R J, Pritchard C C, Shendure J, et al. Classification and characterization of microsatellite instability across 18 cancer types[J]. Nature medicine, 2016, 22(11): 1342.

35.Willis J, Lefterova MI, Artyomenko A, et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel [published online ahead of print August 4, 2019]. Clin Can Res. 

36.Lu SStein JERimm DLWang DW,et al.Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis.JAMA Oncol. 2019 Jul 18.

Jun Wang, Jingwei Sun, Linda N. Liu, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nature Medicine, 2019.

Chin RIChen KUsmani A,et al.Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA(ctDNA).Mol Diagn Ther. 2019 Jun;23(3):311-331.

Wang JChang SLi GSun Y.Application of liquid biopsy in precision medicine: opportunities and challenges.Front Med. 2017 Dec;11(4):522-527.

40.Parikh ARLeshchiner IElagina L,et al.Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers.Nat Med. 2019 Sep;25(9):1415-1421. 

41.GRAIL to Present New Data in Late-Breaking Oral Presentation at the European Society for Medical Oncology (ESMO) 2019 Congress.

42.Head-to-Head Comparison to be Presented at AACR Supports Use of “Blood First” For First-Line Advanced NSCLC Patients. Retrieved February 28, 2019.

43.Schochter FFriedl TWPdeGregorio Aet al.Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions.Cells. 2019 Nov 8;8(11).

44.Su ZWang ZNi Xet al.Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells.Clin Cancer Res. 2019 Aug 15;25(16):5049-5060. 

45.Pentsova EIShah RHTang J,et al.Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid.J Clin Oncol. 2016 Jul 10;34(20):2404-15.

Miller AMShah RHPentsova EI,et al.Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid.Nature. 2019 Jan;565(7741):654-658.

新闻资讯